| Nov 16 |
We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate
|
| Nov 13 |
SELLAS Life Sciences GAAP EPS of -$0.10 beats by $0.03
|
| Nov 13 |
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 5 |
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024
|
| Oct 15 |
SELLAS announces FDA rare pediatric disease designation for its leukemia treatment
|
| Oct 15 |
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia
|
| Oct 10 |
SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
|
| Sep 18 |
Sellas Life Sciences Group Inc (NASDAQ:SLS): A Bull Case Theory
|
| Aug 13 |
SELLAS Life Sciences GAAP EPS of -$0.13 beats by $0.04
|
| Aug 13 |
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
